OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
7091$1176.0057

Living Platform Ltd

Healthcare Facilities & ServicesVerified

Living Platform Ltd has a liquidity position that is characterized by a current ratio of 1.08, indicating that the company has just enough current assets to cover its current liabilities. The company's price-to-book ratio is 3.17, and its price-to-tangible-book ratio is also 3.17, suggesting that the market is valuing the company's equity at a premium relative to its book value. The company's debt-to-equity ratio is 3.6, which is relatively high and indicates a significant reliance on debt financing. In terms of profitability, Living Platform Ltd has a return on equity of 6.3%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets is 0.94%, which is relatively low and suggests that the company is not efficiently using its assets to generate earnings. These metrics are compared against the industry's preferred metrics, and the company's performance appears to be below the median for its industry. The company's revenue is concentrated in a single segment, as there are no disclosed segments beyond the overall healthcare facilities and services operations. Geographically, the company's exposure is primarily within Japan, as the financial data is reported in Japanese Yen and there is no indication of significant international operations. Looking at the growth trajectory, the company's revenue for the latest period is reported at 4,369,434,000 JPY. The analyst estimates for the last actual revenue were 19,204,570,000 JPY, which suggests a significant discrepancy between the reported revenue and the analyst estimates. This discrepancy may indicate either a change in the company's operations or a potential issue with the accuracy of the financial reporting. The risk assessment for Living Platform Ltd indicates a medium level of liquidity risk, with a key flag noting that the company's net cash is negative after subtracting total debt. The dilution risk is assessed as low, which suggests that the company is not expected to issue additional shares that could dilute existing shareholders' equity in the near term. The company's capital structure, with a high debt-to-equity ratio, may also contribute to credit risk, as the company's ability to meet its debt obligations could be affected by changes in interest rates or economic conditions. Recent events related to Living Platform Ltd include the latest financial reporting, which shows a net income of 104,666,000 JPY. The company's operating cash flow is positive at 1,509,635,000 JPY, which is a positive sign for its ability to generate cash from operations. However, the capital expenditure is reported as a negative value of -631,301,000 JPY, which may indicate that the company is investing in new projects or assets. These recent financial activities suggest that the company is actively managing its operations and investments.

30-day price · 7091(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyLiving Platform Ltd
Ticker7091.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Living Platform Ltd provides healthcare services and equipment, primarily generating revenue through its operations in the healthcare facilities and services sector.

Classification. Living Platform Ltd is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

Living Platform Ltd has a liquidity position that is characterized by a current ratio of 1.08, indicating that the company has just enough current assets to cover its current liabilities. The company's price-to-book ratio is 3.17, and its price-to-tangible-book ratio is also 3.17, suggesting that the market is valuing the company's equity at a premium relative to its book value. The company's debt-to-equity ratio is 3.6, which is relatively high and indicates a significant reliance on debt financing. In terms of profitability, Living Platform Ltd has a return on equity of 6.3%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets is 0.94%, which is relatively low and suggests that the company is not efficiently using its assets to generate earnings. These metrics are compared against the industry's preferred metrics, and the company's performance appears to be below the median for its industry. The company's revenue is concentrated in a single segment, as there are no disclosed segments beyond the overall healthcare facilities and services operations. Geographically, the company's exposure is primarily within Japan, as the financial data is reported in Japanese Yen and there is no indication of significant international operations. Looking at the growth trajectory, the company's revenue for the latest period is reported at 4,369,434,000 JPY. The analyst estimates for the last actual revenue were 19,204,570,000 JPY, which suggests a significant discrepancy between the reported revenue and the analyst estimates. This discrepancy may indicate either a change in the company's operations or a potential issue with the accuracy of the financial reporting. The risk assessment for Living Platform Ltd indicates a medium level of liquidity risk, with a key flag noting that the company's net cash is negative after subtracting total debt. The dilution risk is assessed as low, which suggests that the company is not expected to issue additional shares that could dilute existing shareholders' equity in the near term. The company's capital structure, with a high debt-to-equity ratio, may also contribute to credit risk, as the company's ability to meet its debt obligations could be affected by changes in interest rates or economic conditions. Recent events related to Living Platform Ltd include the latest financial reporting, which shows a net income of 104,666,000 JPY. The company's operating cash flow is positive at 1,509,635,000 JPY, which is a positive sign for its ability to generate cash from operations. However, the capital expenditure is reported as a negative value of -631,301,000 JPY, which may indicate that the company is investing in new projects or assets. These recent financial activities suggest that the company is actively managing its operations and investments.
Key takeaways
  • Living Platform Ltd has a high debt-to-equity ratio of 3.6, indicating a significant reliance on debt financing.
  • The company's return on equity is 6.3%, which is a measure of how effectively the company is using shareholders' equity to generate profits.
  • The company's liquidity position is characterized by a current ratio of 1.08, indicating that the company has just enough current assets to cover its current liabilities.
  • The company's price-to-book ratio is 3.17, suggesting that the market is valuing the company's equity at a premium relative to its book value.
  • The company's net income is 104,666,000 JPY, and its operating cash flow is positive at 1,509,635,000 JPY, indicating a positive cash flow from operations.
  • The company's capital expenditure is reported as a negative value of -631,301,000 JPY, which may indicate that the company is investing in new projects or assets.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$4.37B
Gross profit$335.9M
Operating income$46.3M
Net income$104.7M
R&D
SG&A
D&A
SBC
Operating cash flow$1.51B
CapEx-$631.3M
Free cash flow
Total assets$11.19B
Total liabilities$9.53B
Total equity$1.66B
Cash & equivalents$1.13B
Long-term debt$5.98B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.13B$109.7M$56.9M-$1.34B
FY-3$11.63B$465.0M$408.0M-$461.6M
FY-2$13.69B-$230.7M$91.7M-$448.2M
FY-1$16.66B-$21.1M$189.3M-$17.7M
FY0$19.20B$324.9M$365.6M$238.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$8.95B$1.13B$1.59B
FY-3$10.87B$1.35B$1.75B
FY-2$11.41B$1.47B$1.88B
FY-1$11.19B$1.66B$1.13B
FY0$12.12B$2.05B$1.59B
PeriodOCFCapExFCFSBC
FY-4$255.4M-$1.63B-$1.34B
FY-3$443.6M-$1.17B-$461.6M
FY-2$93.0M-$863.8M-$448.2M
FY-1$1.51B-$631.3M-$17.7M
FY0$612.3M-$544.3M$238.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$4.37B$46.3M$104.7M
FQ-6$4.56B$42.0M$47.0M
FQ-5$4.72B$71.5M$55.5M
FQ-4$4.91B$109.9M$56.9M
FQ-3$5.01B$101.4M$206.2M
FQ-2$5.35B$116.5M$89.3M
FQ-1$5.43B$178.7M$89.6M
FQ0$5.63B$151.5M$96.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$11.19B$1.66B$1.13B
FQ-6$11.47B$1.72B$1.37B
FQ-5$11.20B$1.76B$1.02B
FQ-4$11.67B$1.83B$1.28B
FQ-3$12.12B$2.05B$1.59B
FQ-2$12.47B$2.14B$1.25B
FQ-1$12.60B$2.25B$1.41B
FQ0$13.06B$2.35B$1.78B
PeriodOCFCapExFCFSBC
FQ-7$1.51B-$631.3M
FQ-6
FQ-5$207.4M-$235.0M
FQ-4
FQ-3$612.3M-$544.3M
FQ-2
FQ-1$699.5M-$195.8M
FQ0
Valuation
Market price$1176.00
Market cap$5.27B
Enterprise value$10.13B
P/E50.4
Reported non-GAAP P/E
EV/Revenue2.3
EV/Op income218.7
EV/OCF6.7
P/B3.2
P/Tangible book3.2
Tangible book$1.66B
Net cash-$4.85B
Current ratio1.1
Debt/Equity3.6
ROA0.9%
ROE6.3%
Cash conversion14.4%
CapEx/Revenue-14.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
Metric7091Activity
Op margin1.1%5.6% medp25 -4.2% · p75 12.6%below median
Net margin2.4%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin7.7%36.5% medp25 23.7% · p75 65.2%bottom quartile
CapEx / revenue-14.4%-4.9% medp25 -11.5% · p75 -2.0%bottom quartile
Debt / equity360.0%69.3% medp25 7.9% · p75 120.9%top quartile
Observations
IR observations
Last actual EPS82.15 JPY
Last actual revenue19,204,570,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 01:33 UTC#84ab5064
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:48 UTCJob: 6ce198ad